Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression

Cheryl A. Winkler, Houria Hendel, Mary Carrington, Michael W. Smith, George W. Nelson, Stephen J. O'Brien, John Phair, David Vlahov, Lisa Paula Jacobson, Jay Rappaport, Alexandre Vasilescu, Sebastien Bertin-Maghit, Ping An, Wei Lu, Jean Marie Andrieu, François Schächter, Amu Therwath, Jean François Zagury

Research output: Contribution to journalArticle

Abstract

Three haplotypes for the CCR2-CCR5 region previously have been shown to affect AIDS progression; however, it is not known if the protective and accelerating effects of the haplotypes are relatively constant throughout infection or exert their effects early or late in HIV type 1 infection. The authors report the relative contributions to AIDS progression of CCR2 641, CCR5 Δ32, and the CCR5 promoter haplotype +.P1.+ in the GRIV cohort, which included patients representing the extremes of the distribution for AIDS progression: rapid progressors (RP) who developed CD4+ T-cell counts of 3 within 3 years after the last HIV-1-seronegative test and slow progressors (SP) who were HIV-1 infected for ≥8 years with CD4 + T-cell counts of >500/mm3. Comparing the RP with a seroconverter control group including intermediate progressors to AIDS, we observed the early protective effect of CCR5 Δ32 (odds ratio = 0.25; P = 0.007) was similar in strength to the early susceptible effect of CCR5 +.P1.+ (odds ratio = 2.1, P = 0.01). Comparison of the intermediate control group to the SP showed weaker and less significant odd ratios, suggesting that the effect of these factors tended to be stronger on early progession; the tendency towards a disproportionately early effect was significant for CCR5 Δ32 (P = 0.04) but not for CCR5 +.P1.+ (P = 0.12). Follow-up of SP demonstrated that these polymorphisms have little effect after 8 years, because the subset of SP who had progression after study entry had the same genotype distribution as the global population of SP, suggesting that factors other than CCR5 or CCR2 genetic variants must be responsible for the long- term maintenance of nonprogression.

Original languageEnglish (US)
Pages (from-to)1534-1538
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume37
Issue number4
DOIs
StatePublished - Dec 1 2004

Fingerprint

Haplotypes
Disease Progression
HIV-1
Acquired Immunodeficiency Syndrome
Odds Ratio
CD4 Lymphocyte Count
T-Lymphocytes
Control Groups
HIV Infections
Genotype
Infection
Population

Keywords

  • AIDS
  • CCR2
  • CCR5
  • Disease progression
  • Haplotype
  • HIV

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Winkler, C. A., Hendel, H., Carrington, M., Smith, M. W., Nelson, G. W., O'Brien, S. J., ... Zagury, J. F. (2004). Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression. Journal of Acquired Immune Deficiency Syndromes, 37(4), 1534-1538. https://doi.org/10.1097/01.qai.0000127353.01578.63

Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression. / Winkler, Cheryl A.; Hendel, Houria; Carrington, Mary; Smith, Michael W.; Nelson, George W.; O'Brien, Stephen J.; Phair, John; Vlahov, David; Jacobson, Lisa Paula; Rappaport, Jay; Vasilescu, Alexandre; Bertin-Maghit, Sebastien; An, Ping; Lu, Wei; Andrieu, Jean Marie; Schächter, François; Therwath, Amu; Zagury, Jean François.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 37, No. 4, 01.12.2004, p. 1534-1538.

Research output: Contribution to journalArticle

Winkler, CA, Hendel, H, Carrington, M, Smith, MW, Nelson, GW, O'Brien, SJ, Phair, J, Vlahov, D, Jacobson, LP, Rappaport, J, Vasilescu, A, Bertin-Maghit, S, An, P, Lu, W, Andrieu, JM, Schächter, F, Therwath, A & Zagury, JF 2004, 'Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression', Journal of Acquired Immune Deficiency Syndromes, vol. 37, no. 4, pp. 1534-1538. https://doi.org/10.1097/01.qai.0000127353.01578.63
Winkler, Cheryl A. ; Hendel, Houria ; Carrington, Mary ; Smith, Michael W. ; Nelson, George W. ; O'Brien, Stephen J. ; Phair, John ; Vlahov, David ; Jacobson, Lisa Paula ; Rappaport, Jay ; Vasilescu, Alexandre ; Bertin-Maghit, Sebastien ; An, Ping ; Lu, Wei ; Andrieu, Jean Marie ; Schächter, François ; Therwath, Amu ; Zagury, Jean François. / Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression. In: Journal of Acquired Immune Deficiency Syndromes. 2004 ; Vol. 37, No. 4. pp. 1534-1538.
@article{1ead738fbd124cfeae13ff52ee902efe,
title = "Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression",
abstract = "Three haplotypes for the CCR2-CCR5 region previously have been shown to affect AIDS progression; however, it is not known if the protective and accelerating effects of the haplotypes are relatively constant throughout infection or exert their effects early or late in HIV type 1 infection. The authors report the relative contributions to AIDS progression of CCR2 641, CCR5 Δ32, and the CCR5 promoter haplotype +.P1.+ in the GRIV cohort, which included patients representing the extremes of the distribution for AIDS progression: rapid progressors (RP) who developed CD4+ T-cell counts of 3 within 3 years after the last HIV-1-seronegative test and slow progressors (SP) who were HIV-1 infected for ≥8 years with CD4 + T-cell counts of >500/mm3. Comparing the RP with a seroconverter control group including intermediate progressors to AIDS, we observed the early protective effect of CCR5 Δ32 (odds ratio = 0.25; P = 0.007) was similar in strength to the early susceptible effect of CCR5 +.P1.+ (odds ratio = 2.1, P = 0.01). Comparison of the intermediate control group to the SP showed weaker and less significant odd ratios, suggesting that the effect of these factors tended to be stronger on early progession; the tendency towards a disproportionately early effect was significant for CCR5 Δ32 (P = 0.04) but not for CCR5 +.P1.+ (P = 0.12). Follow-up of SP demonstrated that these polymorphisms have little effect after 8 years, because the subset of SP who had progression after study entry had the same genotype distribution as the global population of SP, suggesting that factors other than CCR5 or CCR2 genetic variants must be responsible for the long- term maintenance of nonprogression.",
keywords = "AIDS, CCR2, CCR5, Disease progression, Haplotype, HIV",
author = "Winkler, {Cheryl A.} and Houria Hendel and Mary Carrington and Smith, {Michael W.} and Nelson, {George W.} and O'Brien, {Stephen J.} and John Phair and David Vlahov and Jacobson, {Lisa Paula} and Jay Rappaport and Alexandre Vasilescu and Sebastien Bertin-Maghit and Ping An and Wei Lu and Andrieu, {Jean Marie} and Fran{\cc}ois Sch{\"a}chter and Amu Therwath and Zagury, {Jean Fran{\cc}ois}",
year = "2004",
month = "12",
day = "1",
doi = "10.1097/01.qai.0000127353.01578.63",
language = "English (US)",
volume = "37",
pages = "1534--1538",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression

AU - Winkler, Cheryl A.

AU - Hendel, Houria

AU - Carrington, Mary

AU - Smith, Michael W.

AU - Nelson, George W.

AU - O'Brien, Stephen J.

AU - Phair, John

AU - Vlahov, David

AU - Jacobson, Lisa Paula

AU - Rappaport, Jay

AU - Vasilescu, Alexandre

AU - Bertin-Maghit, Sebastien

AU - An, Ping

AU - Lu, Wei

AU - Andrieu, Jean Marie

AU - Schächter, François

AU - Therwath, Amu

AU - Zagury, Jean François

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Three haplotypes for the CCR2-CCR5 region previously have been shown to affect AIDS progression; however, it is not known if the protective and accelerating effects of the haplotypes are relatively constant throughout infection or exert their effects early or late in HIV type 1 infection. The authors report the relative contributions to AIDS progression of CCR2 641, CCR5 Δ32, and the CCR5 promoter haplotype +.P1.+ in the GRIV cohort, which included patients representing the extremes of the distribution for AIDS progression: rapid progressors (RP) who developed CD4+ T-cell counts of 3 within 3 years after the last HIV-1-seronegative test and slow progressors (SP) who were HIV-1 infected for ≥8 years with CD4 + T-cell counts of >500/mm3. Comparing the RP with a seroconverter control group including intermediate progressors to AIDS, we observed the early protective effect of CCR5 Δ32 (odds ratio = 0.25; P = 0.007) was similar in strength to the early susceptible effect of CCR5 +.P1.+ (odds ratio = 2.1, P = 0.01). Comparison of the intermediate control group to the SP showed weaker and less significant odd ratios, suggesting that the effect of these factors tended to be stronger on early progession; the tendency towards a disproportionately early effect was significant for CCR5 Δ32 (P = 0.04) but not for CCR5 +.P1.+ (P = 0.12). Follow-up of SP demonstrated that these polymorphisms have little effect after 8 years, because the subset of SP who had progression after study entry had the same genotype distribution as the global population of SP, suggesting that factors other than CCR5 or CCR2 genetic variants must be responsible for the long- term maintenance of nonprogression.

AB - Three haplotypes for the CCR2-CCR5 region previously have been shown to affect AIDS progression; however, it is not known if the protective and accelerating effects of the haplotypes are relatively constant throughout infection or exert their effects early or late in HIV type 1 infection. The authors report the relative contributions to AIDS progression of CCR2 641, CCR5 Δ32, and the CCR5 promoter haplotype +.P1.+ in the GRIV cohort, which included patients representing the extremes of the distribution for AIDS progression: rapid progressors (RP) who developed CD4+ T-cell counts of 3 within 3 years after the last HIV-1-seronegative test and slow progressors (SP) who were HIV-1 infected for ≥8 years with CD4 + T-cell counts of >500/mm3. Comparing the RP with a seroconverter control group including intermediate progressors to AIDS, we observed the early protective effect of CCR5 Δ32 (odds ratio = 0.25; P = 0.007) was similar in strength to the early susceptible effect of CCR5 +.P1.+ (odds ratio = 2.1, P = 0.01). Comparison of the intermediate control group to the SP showed weaker and less significant odd ratios, suggesting that the effect of these factors tended to be stronger on early progession; the tendency towards a disproportionately early effect was significant for CCR5 Δ32 (P = 0.04) but not for CCR5 +.P1.+ (P = 0.12). Follow-up of SP demonstrated that these polymorphisms have little effect after 8 years, because the subset of SP who had progression after study entry had the same genotype distribution as the global population of SP, suggesting that factors other than CCR5 or CCR2 genetic variants must be responsible for the long- term maintenance of nonprogression.

KW - AIDS

KW - CCR2

KW - CCR5

KW - Disease progression

KW - Haplotype

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=10044275192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044275192&partnerID=8YFLogxK

U2 - 10.1097/01.qai.0000127353.01578.63

DO - 10.1097/01.qai.0000127353.01578.63

M3 - Article

C2 - 15602133

AN - SCOPUS:10044275192

VL - 37

SP - 1534

EP - 1538

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 4

ER -